Manidipine (Synonyms: CV-4093, Franidipine, (±)-Manidipine) |
| Katalog-Nr.GC17587 |
Manidipin ist ein Kalziumkanalblocker, der klinisch als Antihypertensivum eingesetzt wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 89226-50-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Manidipine is a calcium channel blocker that is used clinically as an antihypertensive. Target: Calcium ChannelManidipine is a dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells. Manidipine was well tolerated in clinical trials, with most adverse effects related to vasodilation [1]. Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. manidipine represents a first-line treatment option for patients with essential mild-to-moderate hypertension [2]. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension [3].
References:
[1]. Cheer, S.M. and K. McClellan, Manidipine: a review of its use in hypertension. Drugs, 2001. 61(12): p. 1777-99.
[2]. McKeage, K. and L.J. Scott, Manidipine: a review of its use in the management of hypertension. Drugs, 2004. 64(17): p. 1923-40.
[3]. Roca-Cusachs, A. and F. Triposkiadis, Antihypertensive effect of manidipine. Drugs, 2005. 65 Suppl 2: p. 11-9.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *